Fatigue Prognostic for Survival in Certain Patients With Myelodysplastic Syndromes
the ONA take:
Self-reported fatigue severity provides prognostic information for survival independent from gold-standard risk classifications in patients with newly diagnosed higher-risk myelodysplastic syndromes, a new study published online ahead of print in the journal The Lancet Oncology has shown.
Because the clinical presentation of myelodysplastic syndromes can be highly variable, researchers sought to evaluate whether self-reported fatigue severity is prognostic for overall survival in higher-risk patients.
For the study, researchers enrolled 280 patients with myelodysplastic syndromes who were enrolled within 6 months of diagnosis with an intermediate-2-risk or high-risk score.
Results showed that the median overall survival from diagnosis was 17 months. Researchers found that high-risk International Prognostic Scoring System (IPSS) score and a higher score for fatigue were independently associated with reduced overall survival. Self-reported fatigue remained a statistically significant prognostic factor for survival in further multivariate analyses.
“Our findings suggest that fatigue assessment should be included in routine diagnostic investigation for these patients and considered as a standard baseline stratification factor in future randomized controlled trials,” the authors conclude.
Self-reported fatigue severity provides prognostic information for newly diagnosed higher-risk myelodysplastic syndromes.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|